Nascent Biotech (OTCMKTS:NBIO) Stock Price Crosses Above 50-Day Moving Average – Here’s What Happened
by Scott Moore · The Cerbat GemNascent Biotech, Inc. (OTCMKTS:NBIO – Get Free Report)’s stock price crossed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $0.00 and traded as high as $0.0003. Nascent Biotech shares last traded at $0.0003, with a volume of 7,500 shares changing hands.
Nascent Biotech Stock Performance
About Nascent Biotech
Nascent Biotech, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation.